Antenatal atazanavir: a retrospective analysis of pregnancies exposed to atazanavir.

Introduction: There are few data regarding the tolerability, safety, or efficacy of antenatal atazanavir. We report our clinical experience of atazanavir use in pregnancy.

Methods: A retrospective medical records review of atazanavir-exposed pregnancies in 12 London centres between 2004 and 2010.

Treatment response and drug resistance in patients infected with HIV type 1 group O viruses.

Information about the efficacy of antiretroviral drugs in HIV-1 group O strains as well on the virus evolution in terms of resistance development in vivo is very limited. We assessed the clinical, immunological, and virological response to antiretroviral therapy as well as the selection of drug resistance in six HIV-1 group O-infected patients. All but one initiated antiretroviral therapy with two nucleoside reverse transcriptase inhibitors (NRTI) plus one protease inhibitor (PI).